

Eva M Comperat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1671458/publications.pdf>

Version: 2024-02-01

142
papers

12,794
citations

81889

39
h-index

25787

108
g-index

155
all docs

155
docs citations

155
times ranked

10164
citing authors

#	ARTICLE	IF	CITATIONS
1	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 761-768.	3.1	10
2	Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies. <i>World Journal of Urology</i> , 2022, 40, 915-927.	2.2	8
3	Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. <i>Modern Pathology</i> , 2022, 35, 344-351.	5.5	40
4	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and T1b). <i>European Urology</i> , 2022, 81, 95-103.	1.9	559
5	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. <i>Molecular Carcinogenesis</i> , 2022, 61, 5-18.	2.7	6
6	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2022, 81, 95-103.	1.9	158
7	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3091-3102.	2.5	2
8	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2022, 8, 972-979.	3.1	3
9	En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. <i>Journal of Urology</i> , 2022, 207, 754-768.	0.4	26
10	Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: are they the same tumors?. <i>World Journal of Urology</i> , 2022, 40, 1949-1959.	2.2	6
11	A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology. <i>World Journal of Urology</i> , 2022, , 1.	2.2	2
12	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 5307-5316.	1.5	6
13	Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound. <i>European Urology</i> , 2022, 82, 261-270.	1.9	11
14	Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer. <i>Biomarkers in Medicine</i> , 2022, 16, 449-459.	1.4	1
15	Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. <i>European Urology Open Science</i> , 2022, 39, 14-21.	0.4	7
16	ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
17	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 82, 82-96.	1.9	15
18	Flat intraurothelial lesions of the urinary bladder—do hyperplasia, dysplasia, and atypia of unknown significance need to exist as diagnostic entities? and how to handle in routine clinical practice. <i>Modern Pathology</i> , 2022, 35, 1296-1305.	5.5	4

#	ARTICLE	IF	CITATIONS
19	Dynamic evaluation of MRI-targeted, systematic and combined biopsy for prostate cancer diagnosis through 10 years of practice in a single institution. <i>World Journal of Urology</i> , 2022, 40, 1661-1668.	2.2	4
20	An introduction to the WHO 5th edition 2022 classification of testicular tumours. <i>Histopathology</i> , 2022, 81, 459-466.	2.9	32
21	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
22	Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expression. <i>Histopathology</i> , 2022, 81, 228-238.	2.9	10
23	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. <i>European Urology Focus</i> , 2022, , .	3.1	4
24	WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. <i>Histopathology</i> , 2022, 81, 426-438.	2.9	39
25	WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. <i>Histopathology</i> , 2022, 81, 447-458.	2.9	10
26	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>European Urology</i> , 2021, 79, 82-104.	1.9	1,152
27	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. <i>European Urology</i> , 2021, 79, 62-79.	1.9	532
28	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	2.5	143
29	A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 637-645.	2.8	17
30	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 295.e1-295.e8.	1.6	6
31	Genetic variability in 13q33 and 9q34 is linked to aggressiveness patterns and a higher risk of progression of non-muscle-invasive bladder cancer at the time of diagnosis. <i>BJU International</i> , 2021, 127, 375-383.	2.5	2
32	Diagnosis of prostate cancer in one day: The benefits of cytology in tumour detection. <i>Cytopathology</i> , 2021, 32, 211-216.	0.7	0
33	Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 764.	2.4	5
34	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	5.5	118
35	Pathological reporting of cystectomy lymph nodes: a retrospective analysis of experience in Paris. <i>World Journal of Urology</i> , 2021, 39, 4029-4035.	2.2	2
36	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	5.5	138

#	ARTICLE	IF	CITATIONS
37	A systematic review and meta-analysis of prognostic impact of different Gleason patterns in ISUP grade group 4. <i>Minerva Urology and Nephrology</i> , 2021, 73, 42-49.	2.5	4
38	More than ancillary records: clinical implications of renal pathology examination in tumor nephrectomy specimens. <i>Journal of Nephrology</i> , 2021, 34, 1833-1844.	2.0	2
39	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. <i>European Urology</i> , 2021, 79, 480-488.	1.9	198
40	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , 2021, 4, 182-191.	5.4	54
41	Editorial for Cribriform architecture prostatic adenocarcinoma in needle biopsy is a strong independent predictor for lymph node metastases in radical prostatectomy (M. Downes et al.) and Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival (K. Chow et al.). <i>European Journal of Cancer</i> , 2021, 148, 430-431.	2.8	0
42	Differential Prognosis and Response of De novo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 2496.	3.7	8
43	Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review. <i>Current Opinion in Urology</i> , 2021, 31, 324-331.	1.8	5
44	Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1172-1178.	1.0	7
45	Single-lesion PSMA protein expression and response to Lu-177 PSMA therapy in patients with castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 5065-5065.	1.6	0
46	Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 9179-9187.	1.5	3
47	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	4.3	20
48	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1122-1131.	0.4	5
49	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. <i>Advances in Anatomic Pathology</i> , 2021, 28, 179-195.	4.3	23
50	Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4355-4361.	2.2	18
51	Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. <i>European Urology Open Science</i> , 2021, 30, 63-66.	0.4	4
52	PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers. <i>World Journal of Urology</i> , 2021, 39, 4067-4071.	2.2	2
53	Comprehensive integrative profiling of upper tract urothelial carcinomas. <i>Genome Biology</i> , 2021, 22, 7.	8.8	31
54	Similarities and Differences in the 2019 ISUP and GUPS Recommendations on Prostate Cancer Grading: A Guide for Practicing Pathologists. <i>Advances in Anatomic Pathology</i> , 2021, 28, 1-7.	4.3	18

#	ARTICLE	IF	CITATIONS
55	Latest Developments and Current Problems in Bladder Cancer. <i>World Journal of Urology</i> , 2021, 39, 4009-4010.	2.2	0
56	Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations. <i>Journal of Personalized Medicine</i> , 2021, 11, 1147.	2.5	1
57	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 927-942.	5.4	40
58	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <i>European Urology Focus</i> , 2020, 6, 479-489.	3.1	72
59	Atlas of Ex Vivo Prostate Tissue and Cancer Images Using Confocal Laser Endomicroscopy: A Project for Intraoperative Positive Surgical Margin Detection During Radical Prostatectomy. <i>European Urology Focus</i> , 2020, 6, 941-958.	3.1	9
60	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 440-448.	1.6	27
61	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 131-144.	5.4	61
62	Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. <i>American Journal of Pathology</i> , 2020, 190, 442-452.	3.8	5
63	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer: An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
64	Pathomics in urology. <i>Current Opinion in Urology</i> , 2020, 30, 823-831.	1.8	10
65	Prostate cancer local staging using biparametric MRI: assessment and comparison with multiparametric MRI. <i>European Journal of Radiology</i> , 2020, 132, 109350.	2.6	23
66	The Genetic Complexity of Prostate Cancer. <i>Genes</i> , 2020, 11, 1396.	2.4	9
67	Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study. <i>Advances in Anatomic Pathology</i> , 2020, 27, 303-310.	4.3	10
68	Squamous Cell Carcinoma of the Bladder Is Not Associated With High-risk HPV. <i>Urology</i> , 2020, 144, 158-163.	1.0	7
69	Pathological and molecular aspects of urothelial carcinomas. <i>Diagnostic Histopathology</i> , 2020, 26, 330-336.	0.4	2
70	Re: Greater Utility of Molecular Subtype Rather than Epithelial-to-mesenchymal Transition (EMT) Markers for Prognosis in High-risk Non-muscle-invasive (HGT1) Bladder Cancer. <i>European Urology</i> , 2020, 78, 764.	1.9	0
71	European Association of Urology Guidelines on Primary Urethral Carcinoma: 2020 Update. <i>European Urology Oncology</i> , 2020, 3, 424-432.	5.4	28
72	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. <i>Scientific Reports</i> , 2020, 10, 701.	3.3	21

#	ARTICLE	IF	CITATIONS
73	What Does COVID-19 Mean for the Pathology-Urology Interaction?. <i>European Urology</i> , 2020, 78, e43-e44.	1.9	9
74	Transurethral resection of bladder and radical cystectomy: Concordance of histology. Are we good enough?. <i>Turkish Journal of Urology</i> , 2020, 46, 354-359.	1.3	4
75	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.9	986
76	Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. <i>Eur Urol</i> 2019;76:413-415. <i>European Urology</i> , 2019, 76, 416-417.	1.9	6
77	What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 625-642.	5.4	88
78	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , 2019, 75, 453-467.	2.9	3
79	MRI for prostate cancer: can computed high b-value DWI replace native acquisitions?. <i>European Radiology</i> , 2019, 29, 5197-5204.	4.5	34
80	Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?. <i>Cancers</i> , 2019, 11, 422.	3.7	45
81	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. <i>European Urology</i> , 2019, 76, 179-186.	1.9	15
82	Therapeutic rationale of targeting BCG and immune checkpoints in non-muscle-invasive bladder cancer: Is this the Future?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 343-345.	1.6	0
83	Evolution of prostate cancer histopathology. <i>Current Opinion in Urology</i> , 2019, 29, 587-592.	1.8	0
84	Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter Nephroureterectomy and Ureterectomy Specimens. <i>American Journal of Surgical Pathology</i> , 2019, 43, e1-e12.	3.7	5
85	SIU-ICUD on bladder cancer: pathology. <i>World Journal of Urology</i> , 2019, 37, 41-50.	2.2	8
86	Reactivity of CK7 across the spectrum of renal cell carcinomas with clear cells. <i>Histopathology</i> , 2019, 74, 608-617.	2.9	18
87	Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results. <i>Hormones and Cancer</i> , 2019, 10, 36-44.	4.9	23
88	Grading of Urothelial Carcinoma and The New World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016. <i>European Urology Focus</i> , 2019, 5, 457-466.	3.1	112
89	Intraoperative Consultation and Macroscopic Handling. <i>American Journal of Surgical Pathology</i> , 2018, 42, e33-e43.	3.7	16
90	Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU: Is DCE still needed?. <i>European Radiology</i> , 2018, 28, 3760-3769.	4.5	22

#	ARTICLE	IF	CITATIONS
91	Renal Pseudo-tumor Related to Renal Splenosis: Imaging Features. <i>Urology</i> , 2018, 114, e11-e15.	1.0	4
92	Changes of Tumourâ€“Nodeâ€“Metastasis Staging in 2017: Concepts and Evolutions in the European and American Continents. <i>European Urology</i> , 2018, 73, 570-571.	1.9	4
93	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydrataseâ€“deficient Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 279-292.	3.7	101
94	Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. <i>European Urology</i> , 2018, 74, 76-83.	1.9	61
95	Dynamic contrastâ€“enhanced imaging in localizing local recurrence of prostate cancer after radiotherapy: Limited added value for readers of varying level of experience. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1012-1023.	3.4	21
96	Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 605-613.	2.8	6
97	Papillary Renal Cell Carcinoma: A Family Portrait. <i>European Urology</i> , 2018, 73, 79-80.	1.9	6
98	Predicting Response to Intravesical Bacillus Calmette-GuÃ©rin Immunotherapy: Are We There Yet? A Systematic Review. <i>European Urology</i> , 2018, 73, 738-748.	1.9	112
99	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. <i>European Urology</i> , 2018, 73, 111-122.	1.9	627
100	Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review. <i>Neurourology and Urodynamics</i> , 2018, 37, 1386-1395.	1.5	50
101	Indication for a Single Postoperative Instillation of Chemotherapy in Nonâ€“muscle-invasive Bladder Cancer: What Factors Should Be Considered?. <i>European Urology Focus</i> , 2018, 4, 525-528.	3.1	8
102	â€œHigh-grade oncocyctic renal tumorâ€“ morphologic, immunohistochemical, and molecular genetic study of 14 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 725-738.	2.8	83
103	Twoâ€“photon optical imaging, spectral and fluorescence lifetime analysis to discriminate urothelial carcinoma grades. <i>Journal of Biophotonics</i> , 2018, 11, e201800065.	2.3	17
104	Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. <i>Human Pathology</i> , 2018, 80, 55-64.	2.0	36
105	Analysis of bladder cancer subtypes in neurogenic bladder tumors. <i>Canadian Journal of Urology</i> , 2018, 25, 9161-9167.	0.0	9
106	EAU Guidelines on Nonâ€“Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. <i>European Urology</i> , 2017, 71, 447-461.	1.9	1,594
107	Re: Analysis of Papillary Urothelial Carcinomas of the Bladder with Grade Heterogeneity: Supportive Evidence for an Early Role of CDKN2A Deletions in the FGFR3 Pathway. <i>European Urology</i> , 2017, 71, 690.	1.9	0
108	Reporting and Staging of Testicular Germ Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2017, 41, e22-e32.	3.7	66

#	ARTICLE	IF	CITATIONS
109	HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 133-136.	2.8	12
110	InÂVivo Multiparametric Ultrasound Imaging of Structural and Functional Tumor Modifications during Therapy. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 2000-2012.	1.5	14
111	Characteristics and clinical significance of histological variants of bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 651-668.	3.8	147
112	Ductal adenocarcinoma of the prostate: Clinical and biological profiles. <i>Prostate</i> , 2017, 77, 1242-1250.	2.3	26
113	<i>NSD1</i> Inactivation and <i>SETD2</i> Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas. <i>Cancer Research</i> , 2017, 77, 4835-4845.	0.9	40
114	Classification of Adult Renal Tumors: An Update. <i>Seminars in Ultrasound, CT and MRI</i> , 2017, 38, 2-9.	1.5	5
115	Eosinophilic, Solid, and Cystic Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 60-71.	3.7	139
116	Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 World Health Organization classification. <i>Histopathology</i> , 2016, 69, 717-726.	2.9	14
117	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. <i>Histopathology</i> , 2016, 69, 441-449.	2.9	82
118	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. <i>Human Molecular Genetics</i> , 2016, 25, 1203-1214.	2.9	38
119	Do We Really Need to Wear Proper Eye Protection When Using Holmium:YAG Laser During Endourologic Procedures? Results from an<i>Ex Vivo</i>Animal Model on Pig Eyes. <i>Journal of Endourology</i> , 2016, 30, 332-337.	2.1	26
120	Relationship between non-suspicious MRI and insignificant prostate cancer: results from a monocentric study. <i>World Journal of Urology</i> , 2016, 34, 673-678.	2.2	14
121	Clear Cell-Papillary Renal Cell Carcinoma of the Kidney Not Associated With End-stage Renal Disease. <i>American Journal of Surgical Pathology</i> , 2015, 39, 873-888.	3.7	83
122	Accuracy of Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates. <i>Journal of Urology</i> , 2015, 194, 669-673.	0.4	61
123	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. <i>Histopathology</i> , 2015, 67, 313-324.	2.9	41
124	VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 2202-2211.	1.5	23
125	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. <i>European Urology</i> , 2015, 68, 868-879.	1.9	804
126	Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score. <i>Journal of Urology</i> , 2015, 194, 1617-1623.	0.4	30

#	ARTICLE	IF	CITATIONS
127	EAU Guidelines on Penile Cancer: 2014 Update. <i>European Urology</i> , 2015, 67, 142-150.	1.9	479
128	Genome-wide interaction study of smoking and bladder cancer risk. <i>Carcinogenesis</i> , 2014, 35, 1737-1744.	2.8	50
129	EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. <i>European Urology</i> , 2014, 65, 778-792.	1.9	868
130	The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease. <i>Cancer Research</i> , 2014, 74, 5808-5818.	0.9	24
131	Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 199-205.	2.8	69
132	EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. <i>European Urology</i> , 2013, 64, 639-653.	1.9	1,053
133	HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 803-809.	2.8	31
134	A Contemporary Update on Pathology Standards for Bladder Cancer: Transurethral Resection and Radical Cystectomy Specimens. <i>European Urology</i> , 2013, 63, 321-332.	1.9	103
135	Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours. <i>World Journal of Urology</i> , 2013, 31, 53-59.	2.2	19
136	EAU Guidelines on Primary Urethral Carcinoma. <i>European Urology</i> , 2013, 64, 823-830.	1.9	134
137	Prognostic Interest in Discriminating Muscularis Mucosa Invasion (T1a vs T1b) in Nonmuscle Invasive Bladder Carcinoma: French National Multicenter Study with Central Pathology Review. <i>Journal of Urology</i> , 2013, 189, 2069-2076.	0.4	58
138	An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. <i>Histopathology</i> , 2013, 63, 756-766.	2.9	35
139	Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma. , 2010, 32, 39-44.		4
140	Effect of Genetic Variability within 8q24 on Aggressiveness Patterns at Diagnosis and Familial Status of Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 5635-5639.	7.0	30
141	Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 443, 115-121.	2.8	109
142	Brief update of the new WHO classification for urothelial carcinoma. <i>Current Opinion in Urology</i> , 0, Publish Ahead of Print, .	1.8	3